Answers are grounded in this paper and cite their sources.
The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.
No takes yet. Share an insight, caveat, or question.
Cazzola et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: